Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Finished

Syst-Onco-Herpes Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.

Coordinator
Fondazione Policlinico Sant'orsola Onlus, Italy
Runs
1 May 2022 to 31 October 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069392

What the project is doing

In the project's own words, from its summary on CORDIS.

Solid tumors, in particular metastatic ones, represent unmet clinical needs and the second cause of death worldwide. Oncolytic viruses (OVs) kill tumors and spare normal cells. They are a distinct class of novel anti-cancer agents, frequently administered by intratumoral injection. A Holy Grail in the innovation of OVs is the possibility to administer them by systemic, e.g. intravenous injection, so that in the human body OVs search for metastases and scavenge them.

The systemic delivery of OVs tackles societal challenges as it meets the needs of metastatic patients, those who die of cancer and need innovative therapies most. The Principal Investigator has generated a family of innovative oncolytic herpesviruses (ReHVs) which specifically target HER2-positive tumors (HER2-ReHVs). In preclinical studies HER2-ReHVs exhibit high specificity for HER2-positive cancers, high anti-tumor efficacy also against metastatic tumors, vaccinate against metastatic-like tumors, and are highly safe.

These properties position ReHVs for systemic delivery. The ReHV technology is protected by a portfolio of patents. The objectives of this Proposal are twofold. Firstly, to improve the systemic delivery of ReHVs by identifying the obstacles that constrain such administration, to develop novel strategies to overcome them, including high-risk high-gain modifications that make ReHVs better suited for the systemic delivery.

Secondly, to carry out initiatives for the technological transfer, i.e. development and commercialization of ReHVs. These include the detailed planning of activities to take ReHVs to the authorization for a First-in-Human clinical experimentation, to develop a business plan and carry out OV market analysis and search for investors. By combining the Development and commercialization initiatives with the technological advancements, this POC is expected to achieve the broader objective of progressing ReHVs into clinical experimentation and ultimately to bring them to patients

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Policlinico Sant'orsola OnlusBolognaItalyCoordinator
Alma Mater Studiorum - Universita Di BolognaBolognaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI